Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

With the future of her cancer treatment in limbo, Natalie Phelps doesn’t know how much longer she can wait. Last month, after months of seeking treatment options for her colorectal cancer, the 43-year ...

UK-based Leucid Bio has dosed the first subject in the multi-centre Phase I AERIAL trial of autologous lateral chimeric ...

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

Colon cancer is the third most common cancer diagnosed in the U.S. It generally begins when cells in a part of the body ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...